Editorial: intravenous to subcutaneous vedolizumab-switch without glitch!
Aliment Pharmacol Ther
.
2022 Jul;56(2):349-350.
doi: 10.1111/apt.16989.
Authors
Vinoth Nadesalingam
1
,
Sreedhar Subramanian
1
Affiliation
1
Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
PMID:
35748843
DOI:
10.1111/apt.16989
No abstract available
Publication types
Editorial
Comment
MeSH terms
Administration, Intravenous
Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Substances
Antibodies, Monoclonal, Humanized
vedolizumab